Welcome to our dedicated page for Syndax Pharmaceuticals SEC filings (Ticker: SNDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detail on financial results, material corporate events, and key regulatory milestones for Syndax’s oncology-focused business.
Recent Forms 8-K filed by Syndax include items on quarterly and year-to-date financial results, where the company furnishes press releases and presentations summarizing revenue from Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr), research and development spending, and operating expense trends. Other 8-K filings document significant events such as U.S. Food and Drug Administration approval of Revuforj for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation, as well as board-level changes.
For investors analyzing SNDX, these SEC documents complement earnings press releases and conference call materials by providing standardized, time-stamped records of the company’s disclosures. They help clarify how Syndax reports collaboration revenue from its agreement with Incyte for Niktimvo, how it describes its cash position and funding horizon, and how it characterizes the impact of regulatory approvals on its business.
On Stock Titan, Syndax filings are updated as new documents are posted to EDGAR, and AI-powered tools can assist in navigating complex language, highlighting items related to product approvals, clinical milestones, financial condition, and governance. Users can review 8-Ks for material events, and, where available, refer to 10-K and 10-Q filings for broader discussions of risk factors, pipeline programs, and the company’s description of its commercial-stage biopharmaceutical operations.
Syndax Pharmaceuticals (SNDX) reported Q3 2025 results. Total revenue reached $45.9 million, driven by $32.0 million in Revuforj product sales and $13.9 million in Niktimvo collaboration revenue. The company posted a net loss of $60.7 million (basic and diluted EPS $(0.70)), reflecting continued investment in commercialization and development.
Operating expenses were $103.3 million, including $56.3 million in R&D and $44.9 million in SG&A. Cash, cash equivalents, and short- and long‑term investments totaled $456.1 million at quarter end, with inventory of $25.0 million. A royalty interest financing liability related to Niktimvo stood at $343.9 million (net).
Year‑to‑date through September 30, revenue was $103.6 million and net loss $217.4 million. Subsequent to quarter end, the FDA approved Revuforj on October 24, 2025 for R/R AML with an NPM1 mutation, and Revuforj was added to the NCCN Guidelines for AML on September 18, 2025.
Syndax Pharmaceuticals, Inc. filed a current report announcing that it released its financial results for the quarter and six months ended September 30, 2025. On November 3, 2025, the company issued a press release and a corporate presentation describing these results, which are included as Exhibits 99.1 and 99.2. The company notes that this earnings information is being furnished rather than filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other SEC filings unless specifically referenced.
Syndax Pharmaceuticals (SNDX) announced FDA approval of Revuforj (revumenib) for the treatment of relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options. The company disclosed the news via a press release and held a conference call on October 24, 2025.
The filing notes forward-looking statements regarding plans to make Revuforj commercially available for this indication. A copy of the press release is furnished as Exhibit 99.1.
Michael A. Metzger, the Chief Executive Officer and a director of Syndax Pharmaceuticals, Inc. (SNDX), reported option exercise and an immediate sale on 09/08/2025. He exercised 157,307 options at an exercise price of $10.90 to acquire 157,307 shares and then sold the same 157,307 shares under a Rule 10b5-1 plan at prices ranging from $16.21 to $17.06. The filings show beneficial ownership figures of 455,968 shares after the exercise and 298,661 shares after the sale. The report states Metzger has 1,319,634 vested options immediately exercisable and 651,241 unvested options remaining. The option exercised was fully vested.
Syndax Pharmaceuticals (SNDX) reported a Notice of Proposed Sale on Form 144 indicating an intended sale of 157,307 common shares through Morgan Stanley Smith Barney (NASDAQ) with an aggregate market value of $2,680,511.28, and an approximate sale date of 09/08/2025. The shares were acquired on 09/08/2025 by exercise of stock options from the issuer, with payment in cash. The filing also discloses a prior sale by Michael Metzger of 7,534 shares on 07/16/2025 for $69,953.19. The filer certifies no undisclosed material adverse information.
Dennis Podlesak, a director of Syndax Pharmaceuticals, reported option exercises and planned sales under a Rule 10b5-1 plan in mid-August 2025. On 08/14/2025, 08/15/2025 and 08/18/2025 he exercised options with a $7.20 strike to acquire blocks of 19,200, 19,200 and 19,200 shares respectively, and contemporaneously reported sales of those shares under the 10b5-1 plan at prices that ranged across the transactions: $13.30–$16.00 (detailed ranges per date provided). Following the reported transactions the Form 4 shows 210,963 shares beneficially owned after acquisitions and 191,763 after sales, and the filer notes he holds 135,000 vested, exercisable options remaining.
Point72 entities and Steven A. Cohen report a 5.0% stake in Syndax Pharmaceuticals (SNDX). As of the close of business on August 15, 2025, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. and Steven A. Cohen each report beneficial ownership of 4,327,952 shares of Syndax common stock, representing 5.0% of the class. The filing shows no sole voting or dispositive power and reports shared voting and shared dispositive power of 4,327,952 shares. The statement is filed jointly pursuant to a Joint Filing Agreement (Exhibit 99.1). The issuer's principal executive office is listed at 730 Third Avenue, 9th Floor, New York, NY 10017.
Syndax Pharmaceuticals (SNDX) Form 144 notice reports a proposed sale of 14,400 common shares through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $226,656. The securities were acquired by exercise of stock options on 08/18/2025 and payment was in cash the same day. The filing also discloses two recent Rule 10b5-1 sales by Dennis G. Podlesak in mid-August totaling 38,400 shares for gross proceeds of $570,928.80 ($298,408.32 and $272,520.48). The signee certifies no undisclosed material adverse information and notes any applicable 10b5-1 plan adoption where relevant.
Syndax Pharmaceuticals Schedule 13G/A shows that Point72-related entities and Steven A. Cohen report shared beneficial ownership of 2,307,824 shares of Syndax common stock, representing 2.7% of the class as of the close of business on June 30, 2025. The filing states Point72 Asset Management exercises shared voting and dispositive power over these shares on behalf of an investment fund it manages; Point72 Capital Advisors is the general partner and Mr. Cohen controls both entities. The filing clarifies the position is not intended to indicate an attempt to influence control of the issuer.
Form 144 notice for SNDX reports a proposed sale of 43,200 shares of common stock through Morgan Stanley Smith Barney LLC on 08/14/2025, with an aggregate market value of $581,040.00. The shares were acquired the same day by exercise of stock options and paid for in cash. The filing lists 86,141,862 shares outstanding, and there are no reported sales by the same person in the prior three months.
The notice confirms the seller represents they have no undisclosed material adverse information and follows Rule 144 procedures for the proposed sale.